Vitrolife nominated for Stora Exportpriset 2010

Vitrolife nominated for Stora Exportpriset 2010

During the year Vitrolife has expanded its business, above all in Asia, through
the establishment of new companies, but has also grown rapidly in already
existing markets outside the domestic market, such as the Middle East and
Europe.

“It is truly pleasing and stimulating for all of us at Vitrolife to have our
efforts to achieve global market coverage within our niche recognized in this
way”, says Magnus Nilsson, CEO.

Stora Exportpriset (the Swedish National Export Prize) is awarded by the Swedish
Trade Council to a Swedish company that has displayed strong development in its
exports in recent years, with successes in several markets. His Majesty the King
of Sweden will hand over the prize when the winner is presented at Stockholm
City Hall on April 19. 




March 16, 2010
Gothenburg

Magnus Nilsson
CEO


Queries should be addressed to: 
Magnus Nilsson, CEO; phone +46 31 721 80 61
Eva Nilsagård, CFO, phone +46 31 721 80 13

________________________________________________________________________________
________________________________________________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. 
     The Fertility product area works with nutrient solutions (media),
cryopreservation products and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to evaluate and maintain organs
outside the body order to select usable organs and keeping them in optimal
condition while waiting for transplantation. The Stem Cell Cultivation product
area works with media and instruments to enable the use and handling of stem
cells for therapeutic purposes. 
     Vitrolife today has approximately 170 employees and the company's products
are sold in more than 85 markets. The company is headquartered in Gothenburg,
Sweden, and there are subsidiaries in USA, Australia, France, Italy, United
Kingdom and Japan. Production facilities are housed in Sweden and USA. 
     The Vitrolife share is listed on NASDAQ OMX Nordic Exchange, Small Cap.
________________________________________________________________________________
________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.